RAS Pathway Mutations and Therapeutics in Vascular Anomalies.

Area of Science:

• Genetics
• Molecular Biology
• Pathology

Background:

• Vascular anomalies (VAs) encompass tumors and malformations (VMs) with abnormal vessel development.
• Complications like coagulopathy and edema cause significant morbidity and mortality.
• RAS/RAF/MAPK pathway mutations are implicated in various VAs.

Purpose of the Study:

• To review RAS pathway mutations in VAs.
• To explore the role of these mutations using model systems.
• To present current and future therapeutic strategies targeting RAS pathways.

Main Methods:

• Literature review of RAS pathway mutations in VAs.
• Analysis of insights from cell and animal models.
• Summary of existing therapies targeting RAS pathways.

Main Results:

• RAS genes (KRAS, NRAS, HRAS) are crucial for cell function, cycling between GDP and GTP states.
• Specific "hot spot" mutations in RAS genes (codons 12, 13, 61) are prevalent in VAs.
• These mutations lead to excessive MAP kinase signaling and uncontrolled cell proliferation.

Conclusions:

• RAS pathway mutations are key drivers of VAs.
• Further understanding of these mutations can inform advanced therapeutic approaches.
• Targeting RAS pathways holds promise for treating patients with VAs.